Holger Stark

[1] Following his doctoral research, he focused on developing new, selective ligands for dopamine D2-like receptors, collaborating with Dr. Pierre Sokoloff from the Unité de Neurobiology et Pharmacologie - INSERM (Paris/France).

He obtained his habilitation in pharmaceutical chemistry in 1999, with a monograph titled “Dopamine D3 receptor ligands as pharmacological tools and potential medicinal products,” maintaining the venia legendi.

[1] Stark commenced his academic career as a C3 professor for pharmaceutical/medicinal chemistry at Johann Wolfgang Goethe University in Frankfurt am Main, ascending to the W3 professorship in 2007.

[2] Stark has authored over 240 original papers, review articles, and book chapters and has been involved in ten international patent families, with 60 national applications.

[6] His research interests extend to various other pharmaceutical and medical domains, including NMDA receptor ligands, sphingolipids, enzyme inhibitors (such as monoamine oxidase and cholinesterase), cyclooxygenase, arachidonate-5-lipoxygenase, and ion channels.